Bayer Presents Latest Data and New Research to Advance Cancer Care within Oncology Portfolio at 2021 ASCO Annual MeetingBusiness Wire • 05/11/21
Bayer's Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 DiabetesBusiness Wire • 05/10/21
Enhanced Bayer Carbon Program Offers Growers New Opportunities in 2021 and BeyondBusiness Wire • 04/19/21
Bayer to Present New Clinical Data in Indolent non-Hodgkin's Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021Business Wire • 04/06/21
Bayer Announces Restructuring of U.S. Corporate Affairs To Support Business Priorities, Accelerated Growth PlansBusiness Wire • 04/06/21
Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory MedicineBusiness Wire • 03/29/21
Bayer AG (BAYZF) CEO Werner Baumann on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/26/21
Bayer's Exposure to Thousands of Cancer Lawsuits Persists as Victims' Lawyers Vow to Continue the FightPRNewsWire • 02/24/21
Bayer to Present Data that Reinforce Established Prostate Cancer Portfolio at 2021 ASCO GU Cancers SymposiumBusiness Wire • 02/08/21
Bayer and Orion Expand Development Program for NUBEQA® (darolutamide) in Prostate CancerBusiness Wire • 02/08/21
Bayer Launches The Nutrient Gap Initiative to Expand Access to Vitamins and Minerals for 50 Million People Annually Worldwide by 2030Business Wire • 02/02/21
Bayer Receives Approval in the UK for Xarelto®▼ (rivaroxaban) to Treat Children With Venous Thromboembolism (VTE) and to Prevent VTE RecurrenceBusiness Wire • 02/01/21